? LEADERSHIP, PLANNING AND EVALUATION Raphael Pollock, MD, PhD serves as Director for The Ohio State University Comprehensive Cancer Center (OSUCCC). Dr. Pollock is assisted by a Senior Leadership team of nationally recognized leaders in cancer research, clinical care, and prevention and education includes Peter Shields, MD (Deputy Director); William Carson, MD (Associate Director for Clinical Research); Electra Paskett, PhD (Associate Director for Population Sciences and Community Outreach); Patrick Green, PhD (Associate Director for Basic Science); Claire Verschraegen, MD (Associate Director for Translational Science); Heather Hampel, MS, LGC (Associate Director for Biospecimen Research); Sharyn Baker, PharmD, PhD (Associate Director for Shared Resources); Lawrence Kirschner, MD, PhD (Associate Director for Education and Training); John Byrd, MD (Senior Advisor) and David Gosky, MA, MBA (Executive Director for Administration). This highly experienced Senior Leadership team works together to: ensure consistency in the shared vision and goals of the OSUCCC; foster synergistic and highly collaborative interactions among the basic, population, translational and clinical research components of the OSUCCC; effectively leverage all available resources at OSU, state and national levels; engage in clinical trials, community outreach, education and mentoring; and oversee all activities of the OSUCCC. Continuous planning and evaluation are key to the development and sustained excellence of the OSUCCC, and helps ensure its strong scientific trajectory. Planning and evaluation by the OSUCCC External Scientific and Internal Advisory Boards (ESAB and IAB, respectively), the Associate Directors Committee (ADC), and other councils provide the Director and Senior Leadership ongoing guidance and support. The ESAB is the primary external mechanism for objective review and oversight of the OSUCCC, including its progress in basic, translational, population and community research, and its leadership and strategic direction. The ADC, Program Leaders Committee, Shared Resource Team Leaders Committee, and IAB (composed of OSU deans and associate deans of research) facilitate internal planning and evaluation. The Executive Council is responsible for the cohesive vision of cancer research and clinical programs of the OSUCCC-James and provides another important internal mechanism for planning and evaluation. Dr. Pollock and the Senior Leadership recently created the OSUCCC-James strategic plan for the next five years, building upon existing strong foundations. The overarching goal of the new plan, entitled Ascending to New Heights, is to drive new discoveries that transform cancer care across the continuum of prevention, treatment and survivorship to improve the health of the OSUCCC catchment area communities. Goals supporting research across the lifespan are informed by data about the cancer burden in the catchment area and through bidirectional communication with community advisory boards. Four major research initiatives (immuno-oncology, cancer engineering, translational genomics, and cancer prevention and survivorship) in the plan will accelerate our vision of creating a cancer-free world, one person, one discovery at a time.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
Qian, Maoxiang; Cao, Xueyuan; Devidas, Meenakshi et al. (2018) TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol 36:591-599
Myers, Regina M; Hill, Brian T; Shaw, Bronwen E et al. (2018) Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer 124:816-825
Nemeth, Julianna M; Thomson, Tiffany L; Lu, Bo et al. (2018) A social-contextual investigation of smoking among rural women: multi-level factors associated with smoking status and considerations for cessation. Rural Remote Health 18:4338
Mace, Thomas A; Shakya, Reena; Pitarresi, Jason R et al. (2018) IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67:320-332
Massengill, James B; Sample, Klarke M; Pilarski, Robert et al. (2018) Analysis of the exome aggregation consortium (ExAC) database suggests that the BAP1-tumor predisposition syndrome is underreported in cancer patients. Genes Chromosomes Cancer 57:478-481
Buteyn, Nathaniel J; Fatehchand, Kavin; Santhanam, Ramasamy et al. (2018) Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. Int Immunol 30:375-383
Orchard, Tonya S; Andridge, Rebecca R; Yee, Lisa D et al. (2018) Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. J Acad Nutr Diet 118:578-588.e1
Reiff, Sean D; Mantel, Rose; Smith, Lisa L et al. (2018) The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discov 8:1300-1315
Pi, Fengmei; Binzel, Daniel W; Lee, Tae Jin et al. (2018) Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol 13:82-89

Showing the most recent 10 out of 2602 publications